Comparison Overview

Zitter Insights, an MMIT Company

VS

Ranbaxy

Zitter Insights, an MMIT Company

1040 Stony Hill Rd, Yardley, Pennsylvania, 19067, US
Last Update: 2025-05-05 (UTC)

As a trusted resource since 1989 and acquired in early 2019, Zitter Insights is a division of MMIT that brings market research and helps address the “why” of market access. Our Zitter Insights panel represents top health plans, PBMs and IDNs to provide meaningful insights to our clients.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 19
Subsidiaries: 2
12-month incidents
0
Known data breaches
1
Attack type number
1

Ranbaxy

Plot No. 90 Sector 32 Gurgaon, Haryana 122001, IN
Last Update: 2025-05-06 (UTC)
Between 750 and 799

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranked 8th amongst the global generic pharmaceutical companies, Ranbaxy today has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company has a global footprint in 49 countries, world-class manufacturing facilities in 11 countries and serves customers in over 125 countries. In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse. The combined entity now ranks among the top 15 pharmaceutical companies, globally. The transformational deal will place Ranbaxy in a higher growth trajectory and it will emerge stronger in terms of its global reach and in its capabilities in drug development and manufacturing. Vision & Aspirations Ranbaxy is driven by its vision to achieve significant business in proprietary prescription products by 2012 with a strong presence in developed markets. The Company aspires to be amongst the Top 5 global generic players and aims at achieving global sales of US $5 Bn by 2012. Financials Ranbaxy was incorporated in 1961 and went public in 1973. For the year 2008, the Company recorded Global Sales of US $ 1,682 Mn, reflecting a growth of 4%. The Company has a balanced mix of revenues from emerging and developed markets that contribute 54% and 39% respectively. In 2008, North America, the Company's largest market contributed sales of US $ 449 Mn, followed by Europe garnering US $ 330 Mn. Business in Asia has been going strong with India clocking sales of around US $ 300 Mn with market leadership in several business segments, backed by strong brand-building skills.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 10,001+
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/zitter-health-insights.jpeg
Zitter Insights, an MMIT Company
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/ranbaxy.jpeg
Ranbaxy
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Zitter Insights, an MMIT Company
100%
Compliance Rate
0/4 Standards Verified
Ranbaxy
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Zitter Insights, an MMIT Company in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Ranbaxy in 2025.

Incident History — Zitter Insights, an MMIT Company (X = Date, Y = Severity)

Zitter Insights, an MMIT Company cyber incidents detection timeline including parent company and subsidiaries

Incident History — Ranbaxy (X = Date, Y = Severity)

Ranbaxy cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/zitter-health-insights.jpeg
Zitter Insights, an MMIT Company
Incidents

Date Detected: 10/2021
Type:Breach
Attack Vector: External System Breach (Hacking)
Blog: Blog
https://images.rankiteo.com/companyimages/ranbaxy.jpeg
Ranbaxy
Incidents

No Incident

FAQ

Ranbaxy company demonstrates a stronger AI Cybersecurity Score compared to Zitter Insights, an MMIT Company company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Zitter Insights, an MMIT Company company has historically faced a number of disclosed cyber incidents, whereas Ranbaxy company has not reported any.

In the current year, Ranbaxy company and Zitter Insights, an MMIT Company company have not reported any cyber incidents.

Neither Ranbaxy company nor Zitter Insights, an MMIT Company company has reported experiencing a ransomware attack publicly.

Zitter Insights, an MMIT Company company has disclosed at least one data breach, while the other Ranbaxy company has not reported such incidents publicly.

Neither Ranbaxy company nor Zitter Insights, an MMIT Company company has reported experiencing targeted cyberattacks publicly.

Neither Zitter Insights, an MMIT Company company nor Ranbaxy company has reported experiencing or disclosing vulnerabilities publicly.

Neither Zitter Insights, an MMIT Company nor Ranbaxy holds any compliance certifications.

Neither company holds any compliance certifications.

Zitter Insights, an MMIT Company company has more subsidiaries worldwide compared to Ranbaxy company.

Zitter Insights, an MMIT Company company employs more people globally than Ranbaxy company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Zitter Insights, an MMIT Company nor Ranbaxy holds SOC 2 Type 1 certification.

Neither Zitter Insights, an MMIT Company nor Ranbaxy holds SOC 2 Type 2 certification.

Neither Zitter Insights, an MMIT Company nor Ranbaxy holds ISO 27001 certification.

Neither Zitter Insights, an MMIT Company nor Ranbaxy holds PCI DSS certification.

Neither Zitter Insights, an MMIT Company nor Ranbaxy holds HIPAA certification.

Neither Zitter Insights, an MMIT Company nor Ranbaxy holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Deck Mate 1 executes firmware directly from an external EEPROM without verifying authenticity or integrity. An attacker with physical access can replace or reflash the EEPROM to run arbitrary code that persists across reboots. Because this design predates modern secure-boot or signed-update mechanisms, affected systems should be physically protected or retired from service. The vendor has not indicated that firmware updates are available for this legacy model.

Risk Information
cvss4
Base: 7.0
Severity: LOW
CVSS:4.0/AV:P/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Deck Mate 2 lacks a verified secure-boot chain and runtime integrity validation for its controller and display modules. Without cryptographic boot verification, an attacker with physical access can modify or replace the bootloader, kernel, or filesystem and gain persistent code execution on reboot. This weakness allows long-term firmware tampering that survives power cycles. The vendor indicates that more recent firmware updates strengthen update-chain integrity and disable physical update ports to mitigate related attack avenues.

Risk Information
cvss4
Base: 7.0
Severity: LOW
CVSS:4.0/AV:P/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Deck Mate 2's firmware update mechanism accepts packages without cryptographic signature verification, encrypts them with a single hard-coded AES key shared across devices, and uses a truncated HMAC for integrity validation. Attackers with access to the update interface - typically via the unit's USB update port - can craft or modify firmware packages to execute arbitrary code as root, allowing persistent compromise of the device's integrity and deck randomization process. Physical or on-premises access remains the most likely attack path, though network-exposed or telemetry-enabled deployments could theoretically allow remote exploitation if misconfigured. The vendor confirmed that firmware updates have been issued to correct these update-chain weaknesses and that USB update access has been disabled on affected units.

Risk Information
cvss4
Base: 7.0
Severity: LOW
CVSS:4.0/AV:P/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Uncontrolled Resource Consumption vulnerability in Legion of the Bouncy Castle Inc. Bouncy Castle for Java FIPS bc-fips on All (API modules), Legion of the Bouncy Castle Inc. Bouncy Castle for Java LTS bcprov-lts8on on All (API modules) allows Excessive Allocation. This vulnerability is associated with program files core/src/main/jdk1.9/org/bouncycastle/crypto/fips/AESNativeCFB.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/fips/AESNativeGCM.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/fips/SHA256NativeDigest.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/fips/AESNativeEngine.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/fips/AESNativeCBC.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/fips/AESNativeCTR.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/engines/AESNativeCFB.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/engines/AESNativeGCM.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/engines/AESNativeEngine.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/engines/AESNativeCBC.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/engines/AESNativeGCMSIV.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/engines/AESNativeCCM.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/engines/AESNativeCTR.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/digests/SHA256NativeDigest.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/digests/SHA224NativeDigest.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/digests/SHA3NativeDigest.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/digests/SHAKENativeDigest.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/digests/SHA512NativeDigest.Java, core/src/main/jdk1.9/org/bouncycastle/crypto/digests/SHA384NativeDigest.Java. This issue affects Bouncy Castle for Java FIPS: from 2.1.0 through 2.1.1; Bouncy Castle for Java LTS: from 2.73.0 through 2.73.7.

Risk Information
cvss4
Base: 5.9
Severity: LOW
CVSS:4.0/AV:L/AC:L/AT:P/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:P/AU:N/R:U/V:C/RE:M/U:Amber
Description

Wasmtime is a runtime for WebAssembly. In versions from 38.0.0 to before 38.0.3, the implementation of component-model related host-to-wasm trampolines in Wasmtime contained a bug where it's possible to carefully craft a component, which when called in a specific way, would crash the host with a segfault or assert failure. Wasmtime 38.0.3 has been released and is patched to fix this issue. There are no workarounds.

Risk Information
cvss4
Base: 2.1
Severity: HIGH
CVSS:4.0/AV:N/AC:H/AT:P/PR:L/UI:P/VC:N/VI:N/VA:L/SC:N/SI:N/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X